Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA

Clinical trial NCT05904626 · RECRUITING

Trial details

NCT number: NCT05904626
Sponsor: Elgan Pharma Ltd.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Intestinal Malabsorption

Start date: 2025-10-28
Primary completion: 2027-06-01
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.